<DOC>
	<DOC>NCT02581631</DOC>
	<brief_summary>This is a signaling study to assess whether nivolumab in combination with brentuximab vedotin is safe and effective in certain subtypes of non-hodgkin lymphomas.</brief_summary>
	<brief_title>A Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Relapsed/refractory diffuse large B cell lymphoma (DLBCL), relapsed/refractory peripheral T cell lymphoma (PTCL) (all subtypes excluding anaplastic large cell lymphoma), relapsed/refractory Cutaneous T cell lymphoma (CTCL) mycosis fungoides/sezary syndrome (MF/SS), relapsed/refractory primary mediastinal B lymphoma (PMBL), and relapsed/refractory mediastinal gray zone lymphoma (MGZL) Expression of CD30 Subjects must be 18 years or older (â‰¥ 15 years for PMBL) Known central nervous system (CNS) lymphomas; Active cerebral/meningeal disease related to the underlying malignancy Active, known, or suspected autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>